295
Participants
Start Date
January 25, 2024
Primary Completion Date
May 31, 2027
Study Completion Date
May 31, 2027
VVD-133214
VVD-133214 will be administered orally and once daily (QD) in 3-week cycles.
Pembrolizumab
Pembrolizumab will be administered by intravenous (IV) infusion at a fixed dose of 200 mg on Day 1 of each 21-day cycle.
ACTIVE_NOT_RECRUITING
Rigshospitalet, København Ø
ACTIVE_NOT_RECRUITING
UZ Leuven Gasthuisberg, Leuven
ACTIVE_NOT_RECRUITING
Alfred Hospital, Melbourne
COMPLETED
Duke University, Durham
ACTIVE_NOT_RECRUITING
Clinica Universidad de Navarra Madrid, Madrid
ACTIVE_NOT_RECRUITING
START Madrid. Centro Integral Oncologico Clara Campal, Madrid
COMPLETED
Clinica Universitaria de Navarra, Pamplona
ACTIVE_NOT_RECRUITING
SCRI Oncology Partners, Nashville
ACTIVE_NOT_RECRUITING
Norton Cancer Institute - MDC, Louisville
ACTIVE_NOT_RECRUITING
Hospital Clinico Universitario de Valencia, Valencia
WITHDRAWN
CLCC Leon Berard Lyon, Lyon
ACTIVE_NOT_RECRUITING
Oklahoma University Health Sciences Center, Oklahoma City
ACTIVE_NOT_RECRUITING
MD Anderson Cancer Center, Houston
ACTIVE_NOT_RECRUITING
City of Hope Cancer Center, Duarte
ACTIVE_NOT_RECRUITING
Gustave Roussy, Villejuif
RECRUITING
City of Hope - Santa Clarita, Valencia
WITHDRAWN
BCCA-Vancouver Cancer Centre, Vancouver
ACTIVE_NOT_RECRUITING
Princess Margaret Cancer Center, Toronto
RECRUITING
Seoul National University Bundang Hospital, Seongnam-si
RECRUITING
Seoul National University Hospital, Seoul
RECRUITING
Asan Medical Center, Seoul
ACTIVE_NOT_RECRUITING
Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Barcelona
ACTIVE_NOT_RECRUITING
Sarah Cannon Research Institute, London
ACTIVE_NOT_RECRUITING
The Christie, Manchester
COMPLETED
Royal Marsden Hospital (Sutton), Sutton
Vividion Therapeutics, Inc.
INDUSTRY